Summary
The comparative pharmacokinetics of Silipide (IdB 1016, a silybin-phosphatidylcholine complex) and silybin were investigated by measuring unconjugated and total plasma silybin levels as well as total biliary and urinary silybin excretion in rats following administration of a single oral dose (200 mg/kg as silybin). Mean peak levels of unconjugated and total silybin after IdB 1016 were 8.17 and 74.23 μg/ml respectively. Mean AUC (0–6 h) values were 9.78 and 232.15 h.μg.ml−1 indicating that about 94% of the plasma silybin is present in a conjugated form. After administration of silybin, plasma levels of both unconjugated and total compound were under the analytical detection limit. Cumulative biliary (0–24 h) and urinary (0–72 h) excretion values after administration of IdB 1016 accounted for 3.73% and 3.26% of the administered dose, respectively. After silybin administration, the biliary and urinary excretion accounted for only 0.001% and 0.032% of the dose respectively. Our results indicate a superior bioavailability of silybin administered orally as IdB 1016. This was due mainly to an impressive increase in gastrointestinal absorption.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Valenzuela A., Guerra R., Videla L.A. (1986): Antioxidant properties of the flavonoids silybin and (+)-cyanidanol-3: comparison with butylated hydroxyanisole and butylated hydroxytoluene. Planta Medica, 19, 438–440.
Valenzuela A., Guerra R. (1986): Differential effect of silybin on the Fe2+-ADP and t-butyl hydroperoxide-induced microsomal lipid peroxidation. Experientia, 42,139–141.
Chasseaud L.F. [Huntingdon Research Centre, unpublished data; c.f. Mennicke W.H. (1975): Zur biologischen Verfügbarkeit und Verstoffwechselung von Silybin. Dtsch. Apoth.Ztg., 115, 1205–1206.
Lang W. (1979): Some aspects of silybin pharmacokinetics in the rat In: Experimentelle und Klinische Hepatologie. III. Internationales Lebersymposium, S. 55, Köln, Nov. 1978.
Mennicke W.H., Lang W., Lorenz D. (1979): Untersuchungen zur Pharmakokinetik von Silymarin. Hepatology, Rapid Literature Review, p. 411. Falk Foundation, Freiburg, Feb. 1979.
Sonnenbichler J., Mattersberger J., Hauser G. (1980): Untersuchungen zum Wirkungsmechanismus von Silybin, III, Aufnahme das Flavanolignans Silybin in Rattenleberzellen. Hoppe-Seyler’s Z. PhysioL Chem., 361, 1751–1756.
Zanolo G., RBM Exp. n. 254, Inverni della Beffa SpA, data on file.
Gabetta B., Zini G.F., Pifferi G. (1989): Spectroscopic studies on IdB 1016, a new flavanolignan complex. Planta Med., 55, 615.
Martinelli E.M., Morazzoni P., Livio S., Uberti E. (1991): Liquid chromatographic assay of silybin in human plasma and urine. J. Liquid Chromatogr., 14, 1285–1296.
Sedman A.J. Wagner J.G. (1976): CSTRIP, a Fortran IV computer program for obtaining initial polyexponential parameter estimates. J. Pharm. Sci., 65, 1006–1010.
Livio S., Seghizzi R., Pifferi G. (1990): Diffusion behaviour of IdB 1016 across artificial and biological membranes. In: Abstract of the Fourth European Congress of Biopharmaceutics and Pharmacokinetics, P-117, Geneva, Apr. 1990.
Conti M., Malandrino S., Magistretti M.J. (1989): Liver protective activity of IdB 1016, a new flavanolignan complex. In: Abstract of Flavonoids in Biology and Medicine, P-29, Singapore, Nov. 1989.
Comoglio A., Leonarduzzi G., Busolin D., et al. (1990): Studies on the antioxidant properties of IdB 1016 a new flavanolignan complex. Free Rad. Res. Commun., 11, 109–115.
Author information
Authors and Affiliations
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/BF03188786.
Rights and permissions
About this article
Cite this article
Morazzoni, P., Magistretti, M.J., Giachetti, C. et al. Comparative bioavailability of Silipide, a new flavanolignan complex, in rats. European Journal of Drug Metabolism and Pharmacokinetics 17, 39–44 (1992). https://doi.org/10.1007/BF03189986
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03189986